Key result
Transcatheter renal denervation shows promise as an alternative for resistant hypertension uncontrolled by triple therapy.
Why the study?
Despite newer antihypertensive drugs and guidelines, achieving good blood pressure control in patients with resistant hypertension remains a major challenge.
Does transcatheter renal sympathetic denervation improve outcomes in patients with resistant hypertension?
Does transcatheter renal sympathetic denervation improve outcomes in patients with resistant hypertension?
Transcatheter renal sympathetic denervation is highlighted as a promising therapeutic alternative for the management of resistant hypertension.
May support evaluation in select resistant hypertension cases; leaves open efficacy confirmation in randomized trials.
Hypertension is one of the most common diseases in the general population. Despite the new generation of antihypertensive drugs and improved guidelines, there is still a poor number of patients with well-controlled hypertension. The particular group is patients with resistant hypertension. It is highly prevalent in the general hypertensive population and good control of those patients remains a great challenge. Renal sympathetic hyperactivity is a response mechanism of resistant hypertension. One of the options for those patients is transcatheter renal sympathetic denervation. Recent studies show promising results and it has become a possible therapeutic alternative to treat this group of patients.
No takes yet. Share an insight, caveat, or question.
A 2023 study conducted a review in Resistant hypertension. Transcatheter renal sympathetic denervation was evaluated. Transcatheter renal denervation is a promising therapeutic alternative for patients with resistant hypertension who fail to achieve blood pressure control with three or more antihypertensive drugs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: